查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2017704

自体免疫疾病治疗市场：2026-2032年全球市场预测（按治疗方法、疾病、给药途径、治疗应用和最终用户划分）

Autoimmune Disease Therapeutics Market by Therapeutic Types, Disease Type, Route of Administration, Therapeutic Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，自体免疫疾病治疗市场价值将达到 1,897.7 亿美元，到 2026 年将成长至 2,095.3 亿美元，到 2032 年将达到 3,823.3 亿美元，复合年增长率为 10.52%。

主要市场统计数据
基准年 2025 1897.7亿美元
预计年份：2026年 2095.3亿美元
预测年份 2032 3823.3亿美元
复合年增长率 (%) 10.52%

简明策略介绍，概述自体免疫疗法市场的临床挑战、商业性现实和相关人员合作。

自体免疫疾病治疗领域的特点是科学进展迅速、监管流程复杂以及支付方期望不断变化，这些因素共同影响研发者和投资者的策略选择。在此背景下，经营团队需要一份简明扼要的概述，将临床挑战与商业性现实相结合，以便更好地制定研发管线优先级、分配资金并与外部合作伙伴开展合作。

科学、商业性和营运创新如何融合，从而重塑自体免疫疾病治疗的临床策略和商业化路径。

科学、技术和政策的变革性转变正在重新定义自体免疫疾病的诊断、治疗和管理方式，其影响波及整个价值链。生物製药的进步、针对小分子化合物的改进以及精准免疫调节方法的成熟，使得治疗策略能够更加明确地着眼于改变疾病进展和实现持续缓解，而不仅仅是控制症状。

本研究评估了不断变化的关税政策如何影响自体免疫疗法供应链的韧性、製造地的决策以及筹资策略。

美国将于2025年实施新的关税措施及相关贸易调整，将对自体免疫疗法的供应链、成本结构和产业计画产生多方面的影响。这些措施不仅会影响活性药物成分和生物製药原料的上游采购，还会影响下游决策，例如最终组装、填充和包装流程的选址以及低温运输物流设施。因此，各公司正在重新审视其筹资策略，以在维持供应连续性的同时，尽可能降低进口成本飙升的影响。

将治疗方法、适应症、给药途径、治疗目标和临床环境与开发和商业化要求联繫起来的综合細項分析。

一套精细的细分框架揭示了治疗方式、适应症、给药途径、治疗目标和最终用户环境如何决定研发重点和商业化策略。治疗类型涵盖多种疗法，例如生技药品（包括降血糖药物、融合蛋白、基因治疗方法和单株抗体）、细胞激素抑制剂、免疫调节剂、免疫抑制剂、非类固醇消炎剂、磷酸二酯酶抑制剂以及小分子化合物（包括皮质类固醇和JAK抑制剂）。每类药物都面临独特的研发挑战、监管证据要求和生产方面的考量，这些都会影响临床试验时间和价值主张。

美洲、欧洲、中东、非洲和亚太地区由于管理体制、支付模式和临床实践模式的差异而产生的区域策略影响。

区域趋势在策略规划中至关重要，因为监管要求、支付方结构和临床实践模式因地区而异。在美洲，重点在于基于价值的报销途径、突破性治疗方法的加速核准项目，以及影响产品上市顺序和合约策略的广泛专科药房和综合医疗保健网络。在这种环境下，健全的真实世界数据项目和早期与支付方的合作对于确保药物可及性和报销结果至关重要。

透过科学创新、製造管理和证据生成能力相结合而脱颖而出的关键竞争和伙伴关係趋势。

领先的研发公司、契约製造组织 (CMO) 和服务供应商之间的竞争动态日益受到策略联盟、垂直整合和有针对性的收购的影响，这些倡议旨在扩大生产规模和提昇科研能力。拥有深厚生物製剂专业知识和单株抗体、融合蛋白和基因疗法专有平台的公司，正透过将临床差异化与生产控制相结合，寻求独特的市场定位，从而降低上市风险并提高品质保证。同时，小规模、更灵活的创新公司则利用伙伴关係开发特化分子和针对特定适应症的药物，通常专注于伴随诊断和患者分层。

切实可行的策略建议，旨在协调临床开发、供应链韧性和市场准入准备，以加快患者获得治疗和商业性成功。

产业领导企业应优先采取一系列切实可行的措施来应对三大挑战：临床差异化、供应链韧性和市场准备。首先，早期临床开发应与支付方的证据要求保持一致，并积极与监管机构合作，以降低与III期临床试验设计和终点选择相关的风险。投资于基于生物标记的患者分层和适应性调查方法可以缩短开发週期，并加强价值提案的论点。其次，供应商网路应多元化，并探索区域性生产和策略伙伴关係关係，以降低关税和物流波动风险，同时在临床和商业化阶段维持品质合规性和稳定的供应。

一种透明、多方面的调查方法，结合了专家访谈、监管分析、科学文献综述和供应链情境评估。

本研究采用多方面方法，结合定性专家访谈、监管和政策分析以及同行评审的科学文献，为策略决策建立了可靠的证据基础。关键的定性资料是透过对临床研究人员、供应链高管、市场进入专家和支付方代表的结构化访谈收集的，从而能够从多个观点从研发到商业化的整个流程。

结论将临床潜力与营运要求和市场进入先决条件相结合，以实现对患者产生有意义的影响。

总之，自体免疫疾病治疗领域正处于转折点，需要在科学突破、严谨的实践应用和成熟的市场进入策略之间取得平衡。先进生物製药、标靶小分子化合物和精准医疗方法的融合为改变疾病进程提供了重要机会，但要实现这一潜力，需要累积临床证据、确保生产可靠性以及与支付方持续合作。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗类型分類的自体免疫疾病治疗市场

  • 降血糖药物
  • 生物製药
    • 融合蛋白
    • 基因治疗
    • 单株抗体
  • 细胞激素抑制剂
  • 免疫调节剂
  • 免疫抑制剂
  • 非类固醇消炎剂（NSAIDs）
  • 磷酸二酯酶抑制剂
  • 低分子化合物
    • 皮质类固醇
    • JAK抑制剂

第九章：自体免疫疾病治疗市场：依疾病类型划分

  • 发炎性肠道疾病
  • 全身性红斑性狼疮
  • 多发性硬化症
  • 银屑病
  • 类风湿性关节炎
  • 1型糖尿病

第十章：自体免疫疾病治疗市场：依给药途径划分

  • 注射药物
    • 肌肉内部
    • 静脉
    • 皮下
  • 口服

第十一章：按治疗应用分類的自体免疫疾病治疗市场

  • 抑制疾病进展
  • 免疫系统调节
  • 疼痛管理
  • 减轻发炎

第十二章：自体免疫疾病治疗市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 研究机构

第十三章：自体免疫疾病治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：自体免疫疾病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：自体免疫疾病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国自体免疫疾病治疗市场

第十七章：中国自体免疫疾病治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exagen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • UCB SA
  • Werfen SA
Product Code: MRR-030C42D3EDB7

The Autoimmune Disease Therapeutics Market was valued at USD 189.77 billion in 2025 and is projected to grow to USD 209.53 billion in 2026, with a CAGR of 10.52%, reaching USD 382.33 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 189.77 billion
Estimated Year [2026] USD 209.53 billion
Forecast Year [2032] USD 382.33 billion
CAGR (%) 10.52%

A concise strategic introduction framing clinical imperatives, commercial realities, and stakeholder alignment across the autoimmune therapeutics landscape

The autoimmune therapeutics landscape is characterized by rapid scientific progress, complex regulatory pathways, and evolving payer expectations that together shape strategic choices for developers and investors. In this environment, a concise introduction that harmonizes the clinical imperatives with commercial realities is essential for executive teams preparing to prioritize pipelines, allocate capital, and engage external partners.

This section sets the stage by outlining prevailing clinical unmet needs, the accelerating role of precision biologics and small molecule agents, and the operational challenges associated with manufacturing, cold chain logistics, and real-world evidence generation. It emphasizes the interplay between clinical trial design and long-term value creation, and it underscores the importance of early alignment with key stakeholders, including clinicians, payers, and specialty pharmacies. Transitional insights highlight where near-term innovations are likely to intersect with systemic constraints, providing a pragmatic foundation for the deeper analyses that follow

How scientific, commercial, and operational innovations converge to reshape clinical strategies and commercialization pathways in autoimmune disease treatment

Transformative shifts across science, technology, and policy are redefining how autoimmune diseases are diagnosed, treated, and managed, with implications that reverberate across the entire value chain. Advances in biologic modalities, improvements in targeted small molecule chemotypes, and maturation of precision immunomodulatory approaches are enabling therapeutic strategies that focus more explicitly on altering disease progression and achieving durable remission rather than merely managing symptoms.

Concurrently, diagnostic improvements and biomarker-driven patient segmentation are reshaping clinical trial cohorts and accelerating adaptive trial designs. These scientific shifts are complemented by commercial and operational transformations, including increased vertical integration among developers, greater reliance on strategic partnerships for manufacturing and distribution, and elevated expectations for digital health adjuncts that improve adherence and monitor safety. Together, these changes necessitate a re-evaluation of traditional commercialization playbooks and call for integrated strategies that align clinical differentiation with scalable manufacturing and payer evidence requirements

Assessing how evolving tariff policies influence supply chain resilience, manufacturing footprint decisions, and procurement strategies for autoimmune therapies

The introduction of new tariff measures and related trade adjustments in the United States in 2025 exerts multifaceted effects across supply chains, cost structures, and operational planning for autoimmune therapeutics. These measures influence upstream procurement of active pharmaceutical ingredients and biologic raw materials, as well as downstream decisions related to where to site final assembly, fill-finish operations, and cold chain logistics. As a result, companies are recalibrating sourcing strategies to mitigate exposure to elevated import costs while preserving supply continuity.

In response, many stakeholders are pursuing near-shoring and regionalization strategies to reduce transit times and regulatory friction, which in turn changes lead times for clinical supplies and commercial inventory. Contract manufacturers and distributors are renegotiating terms to absorb operational complexity and to ensure service level continuity. From a strategic perspective, these dynamics emphasize the importance of supply chain resilience, diversified supplier networks, and scenario planning that integrates tariff sensitivity analyses into regulatory submission timelines and clinical development budgets. Ultimately, organizations that proactively adapt their sourcing and manufacturing footprints will be better positioned to maintain patient access and to protect therapeutic margins

Comprehensive segmentation analysis that links modality, indication, administration route, therapeutic intent, and care setting to development and commercialization imperatives

A nuanced segmentation framework reveals how therapeutic modality, disease indication, administration route, therapeutic intent, and end-user environment jointly inform development priorities and commercialization tactics. Therapeutic types encompass a diverse set of modalities including Antihyperglycemics, Biologics such as Fusion Proteins, Gene Therapy, and Monoclonal Antibodies, Cytokine Inhibitors, Immunomodulators, Immunosuppressants, Nonsteroidal Anti-Inflammatory Drugs, Phosphodiesterase Inhibitors, and Small Molecules which further include Corticosteroids and JAK Inhibitors. Each class carries distinct development challenges, regulatory evidence expectations, and manufacturing considerations that influence time-to-clinic and value narratives.

Disease types range across Inflammatory Bowel Disease, Lupus Erythematosus, Multiple Sclerosis, Psoriasis, Rheumatoid Arthritis, and Type 1 Diabetes, and this distribution of indications drives heterogeneity in endpoint selection, trial duration, and patient recruitment complexity. Route of administration considerations split primarily between Injectable and Oral therapies, with injectable delivery further differentiated by intramuscular, intravenous, and subcutaneous approaches; these factors have direct implications for patient preference, adherence patterns, and the types of support services required at launch. Therapeutic application objectives span disease progression alteration, immune system modulation, pain management, and reduction of inflammation, each demanding tailored clinical programs and differentiated messaging. End-user contexts include ambulatory surgical centers, hospitals, and research institutes, and these settings dictate procurement processes, formulary positioning, and the cadence of post-market evidence collection. By synthesizing these segmentation dimensions, developers can prioritize indications and modalities that align with internal capabilities and external access realities, while payers and providers can better anticipate which therapeutic profiles will offer the most compelling value propositions in distinct care settings

Regional strategic implications tied to divergent regulatory regimes, payer models, and clinical practice patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics are critical to strategic planning because regulatory requirements, payer architectures, and clinical practice patterns diverge substantially across geographies. In the Americas, there is a concentrated emphasis on value-based reimbursement pathways, accelerated regulatory programs for breakthrough therapies, and an extensive network of specialty pharmacies and integrated delivery networks that influence launch sequencing and contracting strategies. This environment rewards robust real-world evidence programs and early payer engagement to secure access and reimbursement outcomes.

Europe, Middle East & Africa presents a mosaic of market access approaches, with varying degrees of centralized assessment and country-specific pricing negotiations; here, alignment with health technology assessment expectations and local clinical guidelines is essential. The region often favors therapeutic approaches that demonstrate clear cost-offsets and long-term benefits. Asia-Pacific markets exhibit rapid adoption of innovative therapies in certain high-capacity health systems, while other countries within the region are characterized by constrained public budgets and tiered access strategies. For these markets, flexible pricing models, partnerships with local manufacturers, and tailored clinical development plans can accelerate uptake. Across all regions, cross-border regulatory harmonization efforts and evolving digital infrastructure will continue to influence strategic choices for clinical development and commercialization

Key competitive and partnership dynamics that deliver differentiation through combined scientific innovation, manufacturing control, and evidence generation capabilities

Competitive dynamics among lead developers, contract manufacturing organizations, and service providers are increasingly shaped by strategic collaborations, vertical integration, and targeted acquisitions that unlock manufacturing scale and scientific capabilities. Companies with deep biologics expertise and proprietary platforms for monoclonal antibodies, fusion proteins, and gene therapies are pursuing differentiated positioning by coupling clinical differentiation with manufacturing control, thereby reducing time-to-market risk and enhancing quality assurance. At the same time, smaller, nimble innovators are leveraging partnerships to advance specialized molecules and niche indications, often focusing on companion diagnostics and patient stratification.

Contract manufacturing and logistics providers that can demonstrate cold chain reliability, flexible capacity, and regulatory compliance are becoming de facto extension partners for developers seeking to minimize supply disruptions. Additionally, organizations that invest in robust real-world evidence generation and patient support programs enhance their negotiating posture with payers and providers. These strategic moves collectively favor entities that can align scientific novelty with operational excellence and payer-relevant evidence generation, creating a competitive advantage for those able to orchestrate end-to-end development and commercialization pathways

Actionable strategic recommendations that align clinical development, supply chain resilience, and market access preparations to accelerate patient access and commercial success

Industry leaders should prioritize a set of pragmatic, actionable steps that address clinical differentiation, supply chain resilience, and market access readiness. First, align early clinical development with payer evidence requirements and engage with regulatory authorities proactively to de-risk pivotal trial design and endpoint selection. Investing in biomarker-driven patient stratification and adaptive trial methodologies can shorten development cycles and strengthen value dossiers. Second, diversify supplier networks and consider regionalized manufacturing or strategic partnerships to mitigate tariff and logistics volatility while maintaining quality compliance and reliable supply for clinical and commercial phases.

Third, design integrated go-to-market strategies that couple clinical benefits with operational support services such as patient assistance, adherence programs, and digital health tools that improve outcomes and reduce total cost of care. Fourth, pursue deliberate collaborations with contract manufacturers, distribution partners, and clinical research organizations to secure capacity and specialized capabilities at critical inflection points. Finally, embed real-world evidence planning into development pathways to support reimbursement discussions across diverse regional systems. By sequencing these actions and tying them to clear milestones, leaders can reduce execution risk and accelerate patient access

Transparent multi-method research methodology combining expert interviews, regulatory analysis, scientific literature review, and supply chain scenario assessments

This research integrates a multi-method approach that combines qualitative expert interviews, regulatory and policy analysis, and synthesis of peer-reviewed scientific literature to produce a robust evidence base for strategic decision-making. Primary qualitative inputs were obtained through structured interviews with clinical investigators, supply chain executives, market access specialists, and payer representatives, enabling triangulation of perspectives across the development and commercialization continuum.

Secondary analysis consisted of a careful review of regulatory guidance, clinical trial registries, and scientific publications to validate modality-specific development pathways and safety profiles. Supply chain and tariff impact assessments were constructed using trade flow data and logistics benchmarks, together with scenario-based sensitivity checks to identify points of vulnerability. Throughout the methodology, cross-validation exercises ensured that conclusions were grounded in observable trends and expert judgment rather than speculation, and transparency around data sources and assumptions supports reproducibility and targeted follow-up analyses

Concluding perspective that synthesizes clinical promise with operational imperatives and market access prerequisites for meaningful patient impact

In conclusion, the autoimmune therapeutics arena is at an inflection point where scientific breakthroughs must be matched with disciplined operational execution and sophisticated market access strategies. The convergence of advanced biologics, targeted small molecules, and precision medicine approaches presents substantial opportunity to alter disease trajectories, but realizing that potential requires alignment across clinical evidence generation, manufacturing reliability, and payer engagement.

Leaders that invest in resilient supply chains, biomarker-enabled development, and integrated commercial support services will be best positioned to transform therapeutic promise into sustainable patient impact. As regulatory and trade landscapes evolve, continuous scenario planning and proactive stakeholder alignment will serve as the differentiating factors between programs that achieve broad access and those that face protracted adoption hurdles

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Autoimmune Disease Therapeutics Market, by Therapeutic Types

  • 8.1. Antihyperglycemics
  • 8.2. Biologics
    • 8.2.1. Fusion Proteins
    • 8.2.2. Gene Therapy
    • 8.2.3. Monoclonal Antibodies
  • 8.3. Cytokine Inhibitors
  • 8.4. Immunomodulators
  • 8.5. Immunosuppressants
  • 8.6. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 8.7. Phosphodiesterase Inhibitors
  • 8.8. Small Molecules
    • 8.8.1. Corticosteroids
    • 8.8.2. JAK Inhibitors

9. Autoimmune Disease Therapeutics Market, by Disease Type

  • 9.1. Inflammatory Bowel Disease
  • 9.2. Lupus Erythematosus
  • 9.3. Multiple Sclerosis
  • 9.4. Psoriasis
  • 9.5. Rheumatoid Arthritis
  • 9.6. Type 1 Diabetes

10. Autoimmune Disease Therapeutics Market, by Route of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Intravenous
    • 10.1.3. Subcutaneous
  • 10.2. Oral

11. Autoimmune Disease Therapeutics Market, by Therapeutic Application

  • 11.1. Disease Progression Alteration
  • 11.2. Immune System Modulation
  • 11.3. Pain Management
  • 11.4. Reduction of Inflammation

12. Autoimmune Disease Therapeutics Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Autoimmune Disease Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Autoimmune Disease Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Autoimmune Disease Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Autoimmune Disease Therapeutics Market

17. China Autoimmune Disease Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. Amgen Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. Beckman Coulter, Inc.
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. BioAgilytix Labs, LLC
  • 18.12. bioMerieux S.A.
  • 18.13. Bristol-Myers Squibb Company
  • 18.14. Eli Lilly and Company
  • 18.15. Exagen, Inc.
  • 18.16. F. Hoffmann-La Roche Ltd.
  • 18.17. GlaxoSmithKline PLC
  • 18.18. Johnson & Johnson Services, Inc.
  • 18.19. Lupin Limited
  • 18.20. Merck & Co., Inc.
  • 18.21. Novartis AG
  • 18.22. Pfizer, Inc.
  • 18.23. Sanofi S.A.
  • 18.24. Siemens Healthineers AG
  • 18.25. Thermo Fisher Scientific Inc.
  • 18.26. Trinity Biotech PLC
  • 18.27. UCB S.A.
  • 18.28. Werfen S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERGLYCEMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERGLYCEMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERGLYCEMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY LUPUS ERYTHEMATOSUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE PROGRESSION ALTERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE PROGRESSION ALTERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE PROGRESSION ALTERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNE SYSTEM MODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNE SYSTEM MODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNE SYSTEM MODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REDUCTION OF INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REDUCTION OF INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REDUCTION OF INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 188. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 190. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 213. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 215. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 217. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 224. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 226. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)